Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=10
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=10
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&lookfor=%22Myeloma%22&type=Subject&page=10
PubPharm (7.806)
91
A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma : A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
92
Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma : Phase 1 Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
93
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma : A Phase 1b, Multicenter, Open-Label, Study to Investigate the Safety and Efficacy of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
94
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols : Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
95
Melphalan Hydrochloride in Treating Participants With Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation : Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule(s) and Dose(s) of Melphalan for Injection (Evomela) as a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
96
Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma : Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
97
Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients : A Single Arm, Response-adapted, Open Label Study of Iberdomide, Weekly Bortezomib and Dexamethasone (IberBd) With Isatuximab Added on Demand for Transplant-ineligible, Newly Diagnosed Multiple Myeloma Patients: the BOREALIS Trial
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
98
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS : Phase 2 Study Applying Innovative Minimal Residual Disease (MRD) Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by Autologous Stem Cell Transplantation (ASCT) - TAURUS
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
99
An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma : An Exploratory Clinical Study of the Safety and Efficacy of NKG2D Chimeric Antigen Receptor NK Cell Injections for the Treatment of Efractory Recurrent Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
100
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma : A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
enthalten in:
ClinicalTrials.gov
| 2024
Wird geladen...
[1]
« Vorheriger
5
6
7
8
9
10
11
12
13
14
15
Nächster »
[781]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
7.806
Aufsätze
7.806
E-Artikel
7.806
E-Ressourcen
Zeitschriftentitel
4.588
WHO International Clinical Trials Registry Plat...
3.218
ClinicalTrials.gov
Thema
7.806
610
6.935
Study Type: Interventional
3.170
Multiple Myeloma
2.647
Neoplasms, Plasma Cell
2.056
Recruitment Status: Not yet recruiting
1.944
Phase: Phase 2
1.671
Phase: Phase 3
1.520
Recruitment Status: Completed
1.376
Recruitment Status: Authorised-recruitment may ...
1.327
Recruitment Status: Recruiting
1.007
Medical Condition: Multiple Myeloma
985
Phase: Phase 1
775
Study Type: Observational
471
Recruitment Status: Active, not recruiting
397
Lymphoma
380
Recruitment Status: Terminated
316
Leukemia
258
Phase: Phase 1/Phase 2
250
Myelodysplastic Syndromes
234
Phase: Phase 1, Phase 2
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
4.854
2020-
2.898
2010-2019
54
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
7.676
Englisch
88
Unbestimmt
14
Spanisch
8
Dänisch
8
Französisch
6
Deutsch
2
Tschechisch
2
Galizisch
2
Kinyarwanda
Alle anzeigen ...
weniger ...
Haven't found what you're looking for?
Wird geladen...